Reta-cagri is a gray-market blend of retatrutide and cagrilintide in one vial. No clinical trial has tested the two compounds together.
Retatrutide is Eli Lilly’s investigational once-weekly agonist of three hormone receptors: GIP, GLP-1 and glucagon. Cagrilintide is Novo Nordisk’s long-acting amylin analogue, which works on biology outside the GLP-1 pathway (Novo Nordisk). The two come from rival companies and have never been developed as a pair. A search of ClinicalTrials.gov in October 2026 returns no registered study that combines them.
Each component has human data on its own or with a different partner. In TRIUMPH-1 (NEJM, September 2026), adults with obesity on retatrutide 12 mg weekly lost a mean 25.0% of body weight at 80 weeks versus 3.9% on placebo, under the treatment-regimen estimand. Cagrilintide’s phase 3 data come from pairing it with semaglutide as CagriSema. In REDEFINE 1 (NEJM, 2025), cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly produced a mean 20.4% loss at 68 weeks versus 3.0% on placebo, under the treatment-policy estimand. Neither result tells you anything about retatrutide and cagrilintide combined.
No. Neither retatrutide nor cagrilintide is FDA-approved as of October 2026, and the FDA says neither can legally be used in compounding.
The FDA’s statement on unapproved GLP-1 drugs, updated October 1, 2026, says retatrutide and cagrilintide are not components of any FDA-approved drug and cannot be compounded under federal law. The same page says the agency has warned companies that sold retatrutide labeled “for research purposes” with dosing instructions for human use. Lilly plans to file retatrutide with the FDA in the first quarter of 2027 (pharmaphorum). Novo Nordisk submitted CagriSema to the FDA in December 2025; that application covers cagrilintide with semaglutide, not cagrilintide alone.
A blend doubles what a lab has to confirm. A useful result identifies both peptides and reports the amount of each, because a single purity figure cannot show whether the vial holds the ratio printed on the label or mostly one compound.
Before trusting a label, check that batch’s published result on our latest tests page or in Janoshik’s public results database. No results are published for this blend in our index yet. When the first published result arrives, a vendor leaderboard appears above.